{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:49:51Z","timestamp":1771307391564,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To explore the efficacy and safety of remimazolam for procedural sedation during ultrasound-guided nerve block administration in patients undergoing abdominal tumor surgery, in order to improve and optimize remimazolam use in procedural sedation and clinical anesthesia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The enrolled patients were randomly divided into three groups: 50 patients in the remimazolam group (R group), 50 patients in the dexmedetomidine group (D group), and 50 patients in the midazolam group (M group). Before administering an ultrasound-guided nerve block, all patients received sufentanil AND remimazolam or midazolam or dexmedetomidine. Remimazolam 5\u00a0mg was administered intravenously in group R, dexmedetomidine 0.6\u00a0\u00b5g\/kg was administered intravenously in group D, and midazolam 0.025\u00a0mg\/kg was administered intravenously in group M. Sedation was evaluated by the Modified Observer\u2019s Assessment of Alertness and Sedation scale.When the Modified Observer\u2019s Alertness\/Sedation (MOAA\/S) score was \u2264\u20092, block operation was started. If the target sedation level was not reached, rescue sedatives of remimazolam 2.5\u00a0mg may be intravenously given in group R, dexmedetomidine 0.4\u00a0\u00b5g\/kg be intravenously given in group D, 0.01\u00a0mg\/kg midazolam may be intravenously given in Group M. Hemodynamic indicators (systolic and diastolic blood pressure, heart rate), pulse oxygen saturation, depth of anesthesia (Narcotrend), MOAA\/S,and the incidences of hypoxemia, injection pain, bradycardia and requirement for rescue sedatives were monitored and recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with the control groups (midazolam and dexmedetomidine groups), the Narcotrend index and MOAA\/S decreased more in the remimazolam group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Compared with the control groups, the incidence of hypoxemia and injection pain was slightly higher in the remimazolam group, but the difference was not statistically significant (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). Compared with the dexmedetomidine group, the incidence of bradycardia was significantly lower in the remimazolam group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Remimazolam can be used safely for procedural sedation during ultrasound-guided nerve block administration in patients undergoing abdominal tumor surgery. The sedation effect is better than that with either midazolam or dexmedetomidine, and sedation can be achieved quickly without obvious hemodynamic fluctuations. Remimazolam is associated with better heart rate stability, and slightly higher incidences of hypoxemia and injection pain than are midazolam and dexmedetomidine (no statistically significant difference). The higher incidence of hypoxemia with remimazolam may be related to enhanced sufentanil opioid analgesia, and the mechanism of injection pain with remimazolam must be studied further and clarified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study was approved by the Ethics Committee of Anhui Provincial Cancer Hospital (Ethical Review 2021, No. 23) and registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.chictr.org.cn\">https:\/\/www.chictr.org.cn<\/jats:ext-link>\u00a0(ChiCTR2000035388). The pre-registration time of this experiment is 09\/08\/2020, due to ethical committee of the hospital met irregularly,the ethical approval time is 21\/06\/2021. The recruitment of patients began after the ethical approval (21\/06\/2021) and registration update (06\/07\/2021).The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12871-022-01927-8","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T03:02:16Z","timestamp":1670468536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of remimazolam for procedural sedation during ultrasound-guided transversus abdominis plane block and rectus sheath block in patients undergoing abdominal tumor surgery: a single-center randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Yimin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingsuo","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"issue":"3","key":"1927_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/ALN.0000000000002043","volume":"128","author":"American Society of Anesthesiologists","year":"2018","unstructured":"American Society of Anesthesiologists. Practice guidelines for moderate procedural sedation and analgesia 2018. Anesthesiology. 2018;128(3):437\u201379.","journal-title":"Anesthesiology"},{"key":"1927_CR2","unstructured":"Acacia Pharma Inc. BYFAVO\u2122 (remimazolam): US prescribing information.\u00a02021. https:\/\/www.accessdata.fda.gov. Accessed 21 May 2021."},{"key":"1927_CR3","doi-asserted-by":"crossref","unstructured":"Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efcacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018;88(3):427\u201337.e6.","DOI":"10.1016\/j.gie.2018.04.2351"},{"issue":"1","key":"1927_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/EJA.0000000000000683","volume":"35","author":"J Hinkelbein","year":"2018","unstructured":"Hinkelbein J, Lamperti M, Akeson J, et al. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. Eur J Anaesthesiol. 2018;35(1):6\u201324.","journal-title":"Eur J Anaesthesiol"},{"issue":"4","key":"1927_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jclinane.2013.11.023","volume":"26","author":"N Bhatia","year":"2014","unstructured":"Bhatia N, Arora S, Jyotsna W, et al. Comparison of posterior and subcostal approaches to ultrasound-guided transverse abdominis plane block for postoperative analgesia in laparoscopic cholecystectomy. J Clin Anesth. 2014;26(4):294\u20139.","journal-title":"J Clin Anesth"},{"key":"1927_CR6","doi-asserted-by":"crossref","unstructured":"Hong S, Kim H, Park J. Analgesic effectiveness of rectus sheath block during open gastrectomy: a prospective double-blinded randomized controlled clinical trial. Medicine (Baltimore). 2019;98(15):e15159.","DOI":"10.1097\/MD.0000000000015159"},{"issue":"7","key":"1927_CR7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/jcm8071018","volume":"8","author":"HW Jeong","year":"2019","unstructured":"Jeong HW, Kim CS, Choi KT, et al. Preoperative versus postoperative Rectus Sheath Block for Acute Postoperative PainRelief after laparoscopic cholecystectomy: a randomized controlled study. J Clin Med. 2019;8(7):1018.","journal-title":"J Clin Med"},{"key":"1927_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40265-020-01299-8","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Remimazolam: first approval. Drugs. 2020;80:625\u201333.","journal-title":"Drugs"},{"key":"1927_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00540-020-02755-1","volume":"34","author":"K Masui","year":"2020","unstructured":"Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!! J Anesth. 2020;34:479\u201382.","journal-title":"J Anesth"},{"issue":"3","key":"1927_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2334\/josnusd.21-0051","volume":"63","author":"S Oka","year":"2021","unstructured":"Oka S, Satomi H, Sekino R, et al. Sedation outcomes for remimazolam, a new benzodiazepine. J Oral Sci. 2021;63(3):209\u201311.","journal-title":"J Oral Sci."},{"key":"1927_CR11","unstructured":"Benzoni T, Cascella M. Procedural sedation. StatPearls. Treasure Island (FL); 2020.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/. Accessed 21 May 2021."},{"key":"1927_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/ACO.0b013e32833b9c9f","volume":"23","author":"V Eichhorn","year":"2010","unstructured":"Eichhorn V, Henzler D, Murphy MF. Standardizing care and monitoring for anesthesia or procedural sedation delivered outside the operating room. Curr Opin Anaesthesiol. 2010;23:494\u20139.","journal-title":"Curr Opin Anaesthesiol"},{"key":"1927_CR13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/00000542-200204000-00031","volume":"96","author":"American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists","year":"2002","unstructured":"American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002;96:1004\u201317.","journal-title":"Anesthesiology"},{"key":"1927_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","volume":"132","author":"J Sch\u00fcttler","year":"2020","unstructured":"Sch\u00fcttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020;132:636\u201351.","journal-title":"Anesthesiology"},{"key":"1927_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/ALN.0000000000003102","volume":"132","author":"A Eisenried","year":"2020","unstructured":"Eisenried A, Sch\u00fcttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II. Pharmacodynamics of Electroencephalogram Efects. Anesthesiology. 2020;132:652\u201366.","journal-title":"Anesthesiology"},{"issue":"3","key":"1927_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.mayocpiqo.2017.10.002","volume":"1","author":"RA Helmers","year":"2017","unstructured":"Helmers RA, Dilling JA, Chafee CR, et al. Overall cost comparison of gastrointestinal endoscopic procedures with endoscopistor anesthesia-supported sedation by activity-based costing techniques. Mayo Clin Proc Innov Qual Outcomes. 2017;1(3):234\u201341.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"2","key":"1927_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1213\/ANE.0b013e31823acb95","volume":"115","author":"JR Sneyd","year":"2012","unstructured":"Sneyd JR. Remimazolam: new beginnings or just a me-too? Anesth Analg. 2012;115(2):217\u20139.","journal-title":"Anesth Analg"},{"issue":"2","key":"1927_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.gie.2017.07.018","volume":"87","author":"DS Early","year":"2018","unstructured":"Early DS, Lightdale JR, Vargo JJ, et al. Guidelines for sedation and anesthesia in GI endoscopy. Gastrointest Endosc. 2018;87(2):327\u201337.","journal-title":"Gastrointest Endosc"},{"key":"1927_CR19","unstructured":"European Medicines Agency. Byfavo (remimazolam): EU summary of product characteristics 2021.\u00a0https:\/\/www.ema.europa.eu\/. Accessed 21 May 2021."}],"updated-by":[{"DOI":"10.1186\/s12871-023-02008-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000}}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-022-01927-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-022-01927-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-022-01927-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T06:03:48Z","timestamp":1675749828000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-022-01927-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1927"],"URL":"https:\/\/doi.org\/10.1186\/s12871-022-01927-8","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12871-023-02008-0","asserted-by":"object"}]},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12871-023-02008-0","URL":"https:\/\/doi.org\/10.1186\/s12871-023-02008-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Anhui Provincial Cancer Hospital (Ethical Review 2021, No. 23) and registered at \u00a0(ChiCTR2000035388). The pre-registration time of this experiment is 09\/08\/2020, due to ethical committee of the hospital met irregularly, the ethical approval time is 21\/06\/2021. The recruitment of patients began after the ethical approval (21\/06\/2021) and registration update (06\/07\/2021).The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"381"}}